UNIVERCELLS
Kate Antrobus, CFA, is a seasoned professional with extensive experience in business leadership and finance within the global health sector. Currently serving as Chief Business Officer, Chief Investment Officer, and Global Health & Finance Lead at UNIVERCELLS since October 2019, Kate also contributes to multiple organizations as a Member of the Board of Trustees for Campaigns in Global Health and a Board Member for Medicines Development for Global Health, Quantoom Biosciences, UNIZIMA, and EXOTHERA. Previous roles include Executive Director at Lion's Head Global Partners and a Board Member for the Stop TB Partnership. Kate's early career involved a position as a Portfolio Analyst at J.P. Morgan Asset Management. Academic credentials include degrees from the University of Oxford, Columbia University, and The London School of Economics and Political Science.
UNIVERCELLS
1 followers
Univercells is a global life sciences company making biologics available to everyone. We operate as a campus of start-ups: five businesses solving different parts of the same puzzle - meeting global demand for bioproduction. Because it is not enough for a drug to exist. To change the world it must be accessible to everyone. Each division of affiliates operates a different part of the healthcare value chain, through a distinct business model: Exothera is a Contract Manufacturing and Development Organization (CDMO) for biologicals, mainly vaccines and viral vectors, with GMP production facilities in Belgium and offering process development and optimization services. https://exothera.world/. Unizima delivers international project management of technology transfer, alongside operational support services (quality, supply chain, digital) and bioproduction training programs, as well as care centers and diagnostics surveillance centers. https://unizima.com/. At Quantoom Biosciences, scientists, engineers and clinicians are committed to solve some of the biggest challenges facing mRNA-based vaccines and therapeutics by developing an end-to-end RNA Platform. This includes DNA and RNA manufacturing and formulation, along with critical reagent supply, from sequence to large-scale production. https://www.quantoom.com/. Thanks to a substantial knowledge of the pharmaceutical industry and a strong scientific background, RLM Consulting provides international regulatory affairs support at all stages of product development, from discovery research through preclinical and clinical testing, up to and beyond submission of the dossier for marketing authorization. http://www.rlmconsulting.be/.